ArticleThe American journal of tropical medicine and hygiene2025
Utility of the Erythema Nodosum Leprosum International Study Severity Scale for Erythema Nodosum Leprosum: A Clinically Supported Critical Appraisal.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythema nodosum leprosum (ENL) is an immune-mediated complication of leprosy. A standardized severity scale based on the clinical signs associated with ENL was developed, piloted, and validated by the Erythema Nodosum Leprosum International Study (ENLIST) group. We conducted a critical appraisal of the ENLIST ENL severity scale using the visit data of eight borderline or lepromatous patients diagnosed with ENL from an outpatient dermatology clinic over a 3-year period. The three most commonly recorded tool criteria observed in the patients were the number, inflammation, and extent of ENL lesions. Fever (including in the preceding 7 days), lymphadenopathy, and inflammation of the joints or digits were rarely encountered (<10%). Score changes reflected treatment progression, with a mean net change of -4.6 over the study period. Most ENLIST scores decreased after immunosuppression was increased (58.5%). Our results suggest that ENLIST accurately reflects ENL severity and treatment. The three tool criteria were not frequently recorded as observed in the patients (<10%). Future studies may be conducted to confirm whether the low frequency of these tool criteria indicates true clinical variability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.